Therapy-Related Acute Myeloid Leukemia 2 Months after Chemoradiotherapy for Esophageal Cancer: A Case Report.
Acute adverse event
Chemoradiotherapy
Esophageal cancer
Therapy-related acute myeloid leukemia
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
03
02
2020
accepted:
07
02
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Therapy-related acute myeloid leukemia (AML) is a rare but potentially fatal adverse event caused by chemotherapy or radiotherapy. Herein we report a patient diagnosed with therapy-related AML 2 months after chemoradiotherapy for esophageal cancer. A 61-year-old man with dysphagia was diagnosed with locally advanced esophageal cancer with para-aortic lymph node metastasis. Laboratory blood test did not reveal any abnormality except mild macrocytic anemia. To alleviate dysphagia due to malignant esophageal stenosis, the patient underwent concurrent chemoradiotherapy of 60 Gy in 30 fractions with cisplatin and 5-fluorouracil at a local area in thoracic esophagus. Dysphagia alleviated during chemoradiotherapy; however, pancytopenia did not recover after the completion of chemoradiotherapy, and general fatigue with fever developed 13 weeks after the last day of chemoradiotherapy. To rule out hematological malignancy, bone marrow biopsy was performed. The bone marrow smear and flow cytometry analysis indicated the development of AML. Chromosomal test revealed a complex karyotype, suggesting that AML was associated with myelodysplastic syndrome. The patient died 1 month after the diagnosis of therapy-related AML. Thus, the findings indicate that therapy-related AML may develop during the acute phase of chemoradiotherapy and bone marrow biopsy is necessary when prolonged pancytopenia exists after chemoradiotherapy.
Identifiants
pubmed: 32308595
doi: 10.1159/000506449
pii: cro-0013-0299
pmc: PMC7154239
doi:
Types de publication
Case Reports
Langues
eng
Pagination
299-303Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest.
Références
Biol Blood Marrow Transplant. 2019 Sep;25(9):1770-1778
pubmed: 31176789
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Eur J Haematol. 2010 Oct;85(4):353-7
pubmed: 20546022
Radiat Oncol. 2018 Jan 18;13(1):7
pubmed: 29347960
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90
pubmed: 20932658
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2019 Mar 7;133(10):1049-1059
pubmed: 30670442
Blood. 2007 Dec 15;110(13):4385-95
pubmed: 17726160
Curr Treat Options Oncol. 2015 Aug;16(8):37
pubmed: 26143266
Am J Hematol. 2015 Mar;90(3):208-14
pubmed: 25421221
Lancet Oncol. 2009 Aug;10(8):751-2
pubmed: 19655431
Cancer Sci. 2015 Apr;106(4):407-12
pubmed: 25640628
Int J Clin Oncol. 2016 Oct;21(5):899-908
pubmed: 26936851
J Radiat Res. 2017 Jan;58(1):106-113
pubmed: 27475126